HALO Stock Up 15% after 10-Day Win Streak
Halozyme Therapeutics (HALO) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 15% return. The company has gained about $1.3 Bil in value over the last 10 days, with its current market capitalization at about $8.8 Bil. The stock remains 51.0% above its value at the end of 2024. This compares with year-to-date returns of 9.5% for the S&P 500.
HALO provides biopharma technology with ENHANZE drug delivery using recombinant hyaluronidase and develops treatments for non-Hodgkin lymphoma and chronic lymphocytic leukemia. After this rally, is HALO still a buy – or is it time to lock in gains? Deep dive with Buy or Sell HALO.
Comparing HALO Stock Returns With The S&P 500
The following table summarizes the return for HALO stock vs. the S&P 500 index over different periods, including the current streak:
- The Smart Way to Own ANET: Collect 10% Before You Even Buy
- Triggers That Could Ignite the Next Rally In Meta Platforms Stock
- Can Coca-Cola Stock Withstand These Pressures?
- Fiserv Stock: Strong Cash Flow Poised for a Re-Rating?
- Comcast Stock Pullback: A Chance to Ride the Uptrend
- Has Accenture Stock Quietly Become a Value Opportunity?
| Return Period | HALO | S&P 500 |
|---|---|---|
| 1D | 0.5% | -0.4% |
| 10D (Current Streak) | 14.8% | 1.0% |
| 1M (21D) | 24.0% | 0.8% |
| 3M (63D) | 32.4% | 11.0% |
| YTD 2025 | 51.0% | 9.5% |
| 2024 | 29.4% | 23.3% |
| 2023 | -35.0% | 24.2% |
| 2022 | 41.5% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has HALO behaved after prior drops? See HALO Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 33 S&P constituents with 3 days or more of consecutive gains and 35 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 16 | 29 |
| 4D | 11 | 3 |
| 5D | 3 | 3 |
| 6D | 3 | 0 |
| 7D or more | 0 | 0 |
| Total >=3 D | 33 | 35 |
Key Financials for Halozyme Therapeutics (HALO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $829.3 Mil | $1.0 Bil |
| Operating Income | $337.6 Mil | $551.5 Mil |
| Net Income | $281.6 Mil | $444.1 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $264.9 Mil | $325.7 Mil |
| Operating Income | $141.5 Mil | $202.4 Mil |
| Net Income | $118.1 Mil | $165.2 Mil |
While HALO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.